Drug Trial Radar · NCT00000620
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Last checked: Nov 19, 2026Latest source record: Nov 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,251
Actual
Start
Sep 1999
Primary completion
Jun 2009
Study completion Dec 2012
Sponsor
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)NIH
- Sponsor type
- NIH
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute on Aging (NIA); National Eye Institute (NEI); Centers for Disease Control and Prevention
- First posted
- Oct 28, 1999
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
Conditions
- Atherosclerosis
- Cardiovascular Diseases
- Hypercholesterolemia
- Hypertension
- Diabetes Mellitus, Type 2
- Diabetes Mellitus
- Coronary Disease
Interventions
Anti-hyperglycemic AgentsDrug
Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
Anti-hypertensive AgentsDrug
Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
Blinded fenofibrate or placebo plus simvastatinDrug
Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.Time frame: 4.9 years
- First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.Time frame: 4.7 years
- First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.Time frame: 4.7 years
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Minneapolis Medical Research Foundation
Minneapolis, Minnesota
Columbia University
New York, New York
Wake Forest University
Winston-Salem, North Carolina
Case Western Reserve University
Cleveland, Ohio
Veterans Affairs
Memphis, Tennessee
University of Washington
Seattle, Washington
McMaster University
Hamilton, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.